A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence

Cell Reports

Volumn 23, Issue 2, 2018, Pages 637-651

  de Souza, Camila Ferreira ^a,b   Sabedot, Thais S ^a,b   Malta, Tathiane M ^a,b   Stetson, Lindsay ^c   Morozova, Olena ^d   Sokolov, Artem ^e   Laird, Peter W ^f   Wiznerowicz, Maciej ^g,h,i   Iavarone, Antonio ^j   Snyder, James ^a   deCarvalho, Ana ^a   Sanborn, Zachary ^k   McDonald, Kerrie L ^l   Friedman, William A ^m   Tirapelli, Daniela ^b   Poisson, Laila ^a   Mikkelsen, Tom ^a   Carlotti, Carlos G ^b   Kalkanis, Steven ^a   Zenklusen, Jean ⁿ   Salama, Sofie R ^d   Barnholtz Sloan, Jill S ^c   Noushmehr, Houtan ^a,b   more..

^a HENRY FORD HEALTH SYSTEM   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d University of California Santa Cruz   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f VAN ANDEL RESEARCH INSTITUTE   (United States)

^g GREATER POLAND CANCER CENTRE   (Poland)

^h POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

ⁱ International Institute for Molecular Oncology   (Poland)

^j NEUROLOGICAL INSTITUTE   (United States)

^k NantOmics LLC   (United States)

^l UNIVERSITY OF NEW SOUTH WALES   (Australia)

^m UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

ⁿ NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

DNA methylation; G CIMP high; G CIMP low; IDH mutation; intra subtype heterogeneity; longitudinal gliomas; malignant transformation and recurrence; predictive biomarkers; stem cell like glioblastoma

Indexed keywords

ISOCITRATE DEHYDROGENASE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR SOX; IDH1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CONTROLLED STUDY; CPG ISLAND; CPG ISLAND METHYLATOR PHENOTYPE; DNA METHYLATION; EPIGENETICS; FEMALE; GENOMIC INSTABILITY; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; IDH GENE; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; RECURRENCE RISK; TUMOR RECURRENCE; BRAIN TUMOR; CANCER GRADING; CANCER STEM CELL; CYTOLOGY; GENETICS; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PHENOTYPE; PROGNOSIS;

ADULT; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CPG ISLANDS; DNA METHYLATION; FEMALE; GENOMIC INSTABILITY; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; PHENOTYPE; PROGNOSIS;

EID: 85044930799     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2018.03.107     Document Type: Article

References (48)

1. Bai, H., Harmancı, A.S., Erson-Omay, E.Z., Li, J., Coşkun, S., Simon, M., Krischek, B., Özduman, K., Omay, S.B., Sorensen, E.A., et al. Integrated genomic characterization of IDH1-mutant glioma malignant progression. Nat. Genet. 48 (2016), 59–66.
2. Baysan, M., Woolard, K., Cam, M.C., Zhang, W., Song, H., Kotliarova, S., Balamatsias, D., Linkous, A., Ahn, S., Walling, J., et al. Detailed longitudinal sampling of glioma stem cells in situ reveals Chr7 gain and Chr10 loss as repeated events in primary tumor formation and recurrence. Int. J. Cancer 141 (2017), 2002–2013.
3. Benjamini, Y., Hochberg, Y., Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. J. Roy. Stat. Soc. B. Met. 57 (1995), 289–300.
4. Bhat, K.P.L., Balasubramaniyan, V., Vaillant, B., Ezhilarasan, R., Hummelink, K., Hollingsworth, F., Wani, K., Heathcock, L., James, J.D., Goodman, L.D., et al. Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell 24 (2013), 331–346.
5. Brat, D.J., Verhaak, R.G., Aldape, K.D., Yung, W.K., Salama, S.R., Cooper, L.A., Rheinbay, E., Miller, C.R., Vitucci, M., Morozova, O., et al., Cancer Genome Atlas Research Network. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N. Engl. J. Med. 372 (2015), 2481–2498.
6. Brennan, C.W., Verhaak, R.G.W., McKenna, A., Campos, B., Noushmehr, H., Salama, S.R., Zheng, S., Chakravarty, D., Sanborn, J.Z., Berman, S.H., et al., TCGA Research Network. The somatic genomic landscape of glioblastoma. Cell 155 (2013), 462–477.
7. Carro, M.S., Lim, W.K., Alvarez, M.J., Bollo, R.J., Zhao, X., Snyder, E.Y., Sulman, E.P., Anne, S.L., Doetsch, F., Colman, H., et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 463 (2010), 318–325.
8. Ceccarelli, M., Barthel, F.P., Malta, T.M., Sabedot, T.S., Salama, S.R., Murray, B.A., Morozova, O., Newton, Y., Radenbaugh, A., Pagnotta, S.M., et al., TCGA Research Network. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164 (2016), 550–563.
9. Cheli, Y., Giuliano, S., Botton, T., Rocchi, S., Hofman, V., Hofman, P., Bahadoran, P., Bertolotto, C., Ballotti, R., Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. Oncogene 30 (2011), 2307–2318.
10. Colaprico, A., Silva, T.C., Olsen, C., Garofano, L., Cava, C., Garolini, D., Sabedot, T.S., Malta, T.M., Pagnotta, S.M., Castiglioni, I., et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res., 44, 2016, e71.
11. Daily, K., Ho Sui, S.J., Schriml, L.M., Dexheimer, P.J., Salomonis, N., Schroll, R., Bush, S., Keddache, M., Mayhew, C., Lotia, S., et al. Molecular, phenotypic, and sample-associated data to describe pluripotent stem cell lines and derivatives. Sci. Data, 4, 2017, 170030.
12. Erson-Omay, E.Z., Henegariu, O., Omay, S.B., Harmancı, A.S., Youngblood, M.W., Mishra-Gorur, K., Li, J., Özduman, K., Carrión-Grant, G., Clark, V.E., et al. Longitudinal analysis of treatment-induced genomic alterations in gliomas. Genome Med., 9, 2017, 12.
13. Heiland, D.H., Ferrarese, R., Claus, R., Dai, F., Masilamani, A.P., Kling, E., Weyerbrock, A., Kling, T., Nelander, S., Carro, M.S., c-Jun-N-terminal phosphorylation regulates DNMT1 expression and genome wide methylation in gliomas. Oncotarget 8 (2017), 6940–6954.
14. Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y.C., Laslo, P., Cheng, J.X., Murre, C., Singh, H., Glass, C.K., Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38 (2010), 576–589.
15. Johannessen, T.A., Mukherjee, J., Viswanath, P., Ohba, S., Ronen, S.M., Bjerkvig, R., Pieper, R.O., Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis. Mol. Cancer Res. 14 (2016), 976–983.
16. Johnson, B.E., Mazor, T., Hong, C., Barnes, M., Aihara, K., McLean, C.Y., Fouse, S.D., Yamamoto, S., Ueda, H., Tatsuno, K., et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343 (2014), 189–193.
17. Kim, H., Zheng, S., Amini, S.S., Virk, S.M., Mikkelsen, T., Brat, D.J., Grimsby, J., Sougnez, C., Muller, F., Hu, J., et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 25 (2015), 316–327.
18. Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., Ziller, M.J., et al., Roadmap Epigenomics Consortium. Integrative analysis of 111 reference human epigenomes. Nature 518 (2015), 317–330.
19. Lathia, J.D., Mack, S.C., Mulkearns-Hubert, E.E., Valentim, C.L.L., Rich, J.N., Cancer stem cells in glioblastoma. Genes Dev. 29 (2015), 1203–1217.
20. Lee, J.-K., Wang, J., Sa, J.K., Ladewig, E., Lee, H.-O., Lee, I.-H., Kang, H.J., Rosenbloom, D.S., Camara, P.G., Liu, Z., et al. Spatiotemporal genomic architecture informs precision oncology in glioblastoma. Nat. Genet. 49 (2017), 594–599.
21. Li, Z., Zhang, L., Ma, Z., Yang, M., Tang, J., Fu, Y., Mao, Y., Hong, X., Zhang, Y., ETV1 induces epithelial to mesenchymal transition in human gastric cancer cells through the upregulation of Snail expression. Oncol. Rep. 30 (2013), 2859–2863.
22. Louis, D.N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W.K., Ohgaki, H., Wiestler, O.D., Kleihues, P., Ellison, D.W., The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 131 (2016), 803–820.
23. Malta, T.M., de Souza, C.F., Sabedot, T.S., Silva, T.C., Mosella, M.Q.S., Kalkanis, S.N., Snyder, J., Castro, A.V.B., Noushmehr, H., Glioma CpG Island Methylator Phenotype (G-CIMP): Biological and Clinical Implications. Neuro-oncol., 2017, 10.1093/neuonc/nox183.
24. Malta, T.M., Sokolov, A., Gentles, A.J., Burzykowski, T., Poisson, L., Weinstein, J.N., Kamińska, B., Huelsken, J., Omberg, L., Gevaert, O., et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell, 173, 2018, 10.1016/j.cell.2018.03.034 Published online April 5, 2018.
25. Mazor, T., Pankov, A., Johnson, B.E., Hong, C., Hamilton, E.G., Bell, R.J.A., Smirnov, I.V., Reis, G.F., Phillips, J.J., Barnes, M.J., et al. DNA methylation and somatic mutations converge on the cell cycle and define similar evolutionary histories in brain tumors. Cancer Cell 28 (2015), 307–317.
26. Mazor, T., Chesnelong, C., Pankov, A., Jalbert, L.E., Hong, C., Hayes, J., Smirnov, I.V., Marshall, R., Souza, C.F., Shen, Y., et al. Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1. Proc. Natl. Acad. Sci. U.S.A. 114 (2017), 10743–10748.
27. 1 controls self-renewal and pluripotency of human embryonic stem cells by regulating the cell cycle, Brachyury and Twist. Cell Cycle 10 (2011), 1435–1447.
28. Mur, P., Mollejo, M., Ruano, Y., de Lope, Á.R., Fiaño, C., García, J.F., Castresana, J.S., Hernández-Laín, A., Rey, J.A., Meléndez, B., Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors. Acta Neuropathol. 126 (2013), 277–289.
29. Noushmehr, H., Weisenberger, D.J., Diefes, K., Phillips, H.S., Pujara, K., Berman, B.P., Pan, F., Pelloski, C.E., Sulman, E.P., Bhat, K.P., et al., Cancer Genome Atlas Research Network. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17 (2010), 510–522.
30. Ostrom, Q.T., Gittleman, H., Xu, J., Kromer, C., Wolinsky, Y., Kruchko, C., Barnholtz-Sloan, J.S., CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2009. Neuro-oncol. 18:suppl_5 (2016), v1–v75.
31. Ozawa, T., Riester, M., Cheng, Y.-K., Huse, J.T., Squatrito, M., Helmy, K., Charles, N., Michor, F., Holland, E.C., Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. Cancer Cell 26 (2014), 288–300.
32. Parsons, D.W., Jones, S., Zhang, X., Lin, J.C.-H., Leary, R.J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G.L., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321 (2008), 1807–1812.
33. Phillips, H.S., Kharbanda, S., Chen, R., Forrest, W.F., Soriano, R.H., Wu, T.D., Misra, A., Nigro, J.M., Colman, H., Soroceanu, L., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9 (2006), 157–173.
34. Salomonis, N., Dexheimer, P.J., Omberg, L., Schroll, R., Bush, S., Huo, J., Schriml, L., Ho Sui, S., Keddache, M., Mayhew, C., et al. Integrated genomic analysis of diverse induced pluripotent stem cells from the Progenitor Cell Biology Consortium. Stem Cell Reports 7 (2016), 110–125.
35. Sanai, N., Chang, S., Berger, M.S., Low-grade gliomas in adults. J. Neurosurg. 115 (2011), 948–965.
36. Sharma, S., Kelly, T.K., Jones, P.A., Epigenetics in cancer. Carcinogenesis 31 (2010), 27–36.
37. Shaulian, E., Karin, M., AP-1 as a regulator of cell life and death. Nat. Cell Biol. 4 (2002), E131–E136.
38. Singh, S.K., Hawkins, C., Clarke, I.D., Squire, J.A., Bayani, J., Hide, T., Henkelman, R.M., Cusimano, M.D., Dirks, P.B., Identification of human brain tumour initiating cells. Nature 432 (2004), 396–401.
39. Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J.B., Belanger, K., Brandes, A.A., Marosi, C., Bogdahn, U., et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352 (2005), 987–996.
40. Stupp, R., Hegi, M.E., Mason, W.P., van den Bent, M.J., Taphoorn, M.J.B., Janzer, R.C., Ludwin, S.K., Allgeier, A., Fisher, B., Belanger, K., et al. European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups, National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10 (2009), 459–466.
41. Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.-A., Jones, D.T.W., Konermann, C., Pfaff, E., Tönjes, M., Sill, M., Bender, S., et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22 (2012), 425–437.
42. Triche, T.J., Weisenberger, D.J., Van Den Berg, D., Laird, P.W., Siegmund, K.D., Low-level processing of Illumina Infinium DNA Methylation BeadArrays. Nucleic Acids Res., 41, 2013, e90.
43. Turcan, S., Rohle, D., Goenka, A., Walsh, L.A., Fang, F., Yilmaz, E., Campos, C., Fabius, A.W.M., Lu, C., Ward, P.S., et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483 (2012), 479–483.
44. Verhaak, R.G.W., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D., Miller, C.R., Ding, L., Golub, T., Mesirov, J.P., et al., Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17 (2010), 98–110.
45. Vescovi, A.L., Galli, R., Reynolds, B.A., Brain tumour stem cells. Nat. Rev. Cancer 6 (2006), 425–436.
46. Wang, J., Cazzato, E., Ladewig, E., Frattini, V., Rosenbloom, D.I.S., Zairis, S., Abate, F., Liu, Z., Elliott, O., Shin, Y.-J., et al. Clonal evolution of glioblastoma under therapy. Nat. Genet. 48 (2016), 768–776.
47. Yan, H., Parsons, D.W., Jin, G., McLendon, R., Rasheed, B.A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G.J., et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360 (2009), 765–773.
48. Zhang, Y., Wilson, R., Heiss, J., Breitling, L.P., Saum, K.-U., Schöttker, B., Holleczek, B., Waldenberger, M., Peters, A., Brenner, H., DNA methylation signatures in peripheral blood strongly predict all-cause mortality. Nat. Commun., 8, 2017, 14617.